CoChat

Clonal replacement of tumor-specific T cells following PD-1 blockade

Open access

Published version of a preprint

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Abstract

Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the clinical care of patients with cancer 1. However, whether the T cell response to checkpoint blockade relies on reinvigoration of pre-existing tumor-infiltrating lymphocytes or on recruitment of novel T cells remains unclear 2-4. Here we performed paired single-cell RNA and T cell receptor sequencing on 79,046 cells from site-matched tumors from patients with basal or squamous cell carcinoma before and after anti-PD-1 therapy. Tracking T cell receptor clones and transcriptional phenotypes revealed coupling of tumor recognition, clonal expansion and T cell dysfunction marked by clonal expansion of CD8+CD39+ T cells, which co-expressed markers of chronic T cell activation and exhaustion. However, the expansion of T cell clones did not derive from pre-existing tumor-infiltrating T lymphocytes; instead, the expanded clones consisted of novel clonotypes that had not previously been observed in the same tumor. Clonal replacement of T cells was preferentially observed in exhausted CD8+ T cells and evident in patients with basal or squamous cell carcinoma. These results demonstrate that pre-existing tumor-specific T cells may have limited reinvigoration capacity, and that the T cell response to checkpoint blockade derives from a distinct repertoire of T cell clones that may have just recently entered the tumor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0522-3

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

See all 1,534

Metadata

Authors
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., Gupta, R. K., Curtis, C., Bucktrout, S. L., Davis, M. M., Chang, A. L. S., & Chang, H. Y.
Affiliations
  • Stanford Medicine (US)
  • Parker Institute for Cancer Immunotherapy (US)
  • iRepertoire (United States) (US)
  • Stanford University (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
  • Satpathy, Ansuman T.
  • Chang, Anne Lynn S.
  • Chang, Howard Y.
Venue
Nature Medicine
Published
2019-07-29
Volume
25
Issue
8
Pages
1251-1259
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2966465234
Cited by
1,534
References
75
Citations by year
2026: 193 · 2025: 199 · 2024: 229 · 2023: 243 · 2022: 223 · 2021: 238 · 2020: 180 · 2019: 27
FWCI
69.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Science Foundation (DGE-165651 8, 1656518)
  • Burroughs Wellcome Fund
  • Parker Institute for Cancer Immunotherapy
  • Human Vaccines Project
  • Nature
  • National Institutes of Health (1s10od018220-01, P50-HG007735)
  • National Heart, Lung, and Blood Institute (L30 HL134161)
  • National Human Genome Research Institute (RM1HG007735, P50HG007735)
  • National Cancer Institute (K08CA230188, L30 CA134161, R35CA209919, K23CA211793, P30CA124435)
  • National Institute of Allergy and Infectious Diseases (U19AI057229)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
anti-PD-1 therapy, T cell exhaustion, clonal replacement, T cell receptor repertoire, tumor-infiltrating lymphocytes, CD8+ T cells, basal cell carcinoma, squamous cell carcinoma, T cell reinvigoration, single-cell RNA sequencing, T cell receptor sequencing
MeSH terms
Basal Cell Carcinoma, Carcinoma, Squamous Cell, Humans, Immunotherapy, Receptors, Antigen, T-Cell, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Sequence Analysis, RNA, T Cell Transcription Factor 1, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clonal replacement of tumor-specific T cells following PD-1 blockade. https://app.cochat.ai/papers/10.1038/s41591-019-0522-3
The paper
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., Gupta, R. K., Curtis, C., Bucktrout, S. L., Davis, M. M., Chang, A. L. S., & Chang, H. Y. (2019). Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature Medicine. https://doi.org/10.1038/s41591-019-0522-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.